1 CTRP Registration Abbreviated Participating Sites Templa

The Clinical Trials Reporting Program (CTRP) Database (NCI)

Attach_5D_CTRP_Registry_Abbreviated_Batch_Upload_Template.xls

Registration for the Clinical Trials Reporting Program (CTRP) Database (NCI)

OMB: 0925-0600

Document [xlsx]
Download: xlsx | pdf

Overview

Disclaimer
Readme First
Template Instructions
Sample
Abbreviated Trial Data Spec
2-letter state_province


Sheet 1: Disclaimer



Sheet 2: Readme First

CTRP Trial Registration Batch Upload Specification for Abbreviated Trials


























About this Document












This document provides you with everything you need to upload clinical trial data to the CTRP Trial Registration system, including the following:












Template Instructions






The Template Instructions worksheet provides detailed instructions for preparing your data and uploading them to the system.











Sample Trial Data






The Sample Trial Data worksheet provides an example of what a typical batch upload file looks like.





Note: A batch upload file must contain only one (1) worksheet (tab)











Batch Upload Data Element Specifications






The specifications worksheet includes the following information:





1 Data elements




2 Order in which the data elements must be presented




3 Data element requirements. Requirements differ for original updated, and amended submissions.




4 Valid values. The system accepts only those values listed in this document.




5 Comments. Additional information that helps you to ensure successful upload of your data.










State and Provence Codes






The State and Province Codes worksheet lists the 2- or 3-letter state/province/territory codes for the United States, Canada, and Australia.





Sheet 3: Template Instructions

How to Submit Abbreviated Trial Data to the CTRP Trial Registration System


















Before You Begin


















Contact the CTRO at [email protected] to request approval for sending batch files to CTRP. Include your login name, first and last names, and email address stored in your CTRP profile.








Note: Once you have received approval, you do not have to request approval for subsequent batches.




























Main Steps for Uploading Your Data


















1 Prepare the trial data file







2 Email your files to the CTRO at [email protected]

















Note: CTRO staff will register your trials using your batch file data. As the trial submitter, the CTRO maintains trial ownership by default.








To transfer trial ownership email the CTRO with the first name, last name and email address of the person who will manage your registered trials. The new owner must be a registered CTRP account holder.


















Preparing Trial Data Files


















1 Ensure that your trial conforms to the supported criteria. This template supports the following:


















* Interventional trials







* Abbreviated trials (Summary 4 Funding Sponsor Category is Industrial)







* Updates to abbreviated CTRP trials with the processing status "Accepted" and beyond







* 100 trials per data file
















2 Prepare an Excel spreadsheet (.xls) containing the mandatory and optional data for the trial(s) as specified in this document.


















You must adhere to the following requirements:








* List trial elements required for registration in the order specified in the Abbreviated Trial Data Spec tab in this spreadsheet.








* Do not change the spelling of data elements or valid values. Changes to spelling or to the order of the trial elements will cause the upload to fail. Similarly, the addition of new/extra trial elements will also cause a failure.








* Conform to the valid values guidelines when entering trial data. Valid values for each of the trial elements, where applicable, are listed under Column D in the Abbreviated Trial Data Spec tab in this spreadsheet.








* Identify each trial uniquely. For example, append your cancer center unique trial identifier to the file name.








* If you provide an NCT number the primary purpose, phase, disease and intervention data are not required.








* If a trial is identified as a duplicate to an existing trial, you can request to add your organization information to the existing trial as a participating site using the same template or create a separate request using the Participating Sites Template for abbreviated trials and email it to the CTRO at [email protected].








* If more than one disease or intervention is included, list them on additional lines, one per line when adding local trial identifier to the first column (see Sample Trial Data tab).








* List persons and organizations with PO-IDs.









Note: You can request a list of CTRP persons and organizations along with PO-IDs from the CTRO at [email protected].








Or, you can use the organization/person lookup features in the CTRP Trial Registration application to search for PO-IDs.

























Emailing Your Files


















Email your file as an attachment to the CTRO at [email protected].




























For detailed instructions for registering trials, refer to the NCI CTRP Reporting Program Registration Site User's Guide at:









https://wiki.nci.nih.gov/x/7qViAw








Sheet 4: Sample

Local Trial Identifier Submission Type NCI Trial Identifier [Submitting Organization] Organization PO-ID [Submitting Organization] Name [Submitting Organization] Street Address [Submitting Organization] City [Submitting Organization] State/Province [Submitting Organization] Zip/Postal code [Submitting Organization] Country [Submitting Organization] Email Address [Submitting Organization] Phone [Submitting Organization] TTY [Submitting Organization] FAX [Submitting Organization] URL [Submitting Organization] Organization Type Is Submitting Organization a NCI Designated Cancer Center? [Lead Organization] CTEP Organization PO-ID [Lead Organization] Name [Lead Organization] Street Address [Lead Organization] City [Lead Organization] State/Province [Lead Organization] Zip/Postal code [Lead Organization] Country [Lead Organization] Email Address [Lead Organization] Phone [Lead Organization] TTY [Lead Organization] FAX [Lead Organization] URL [Lead Organization] Organization Type Lead Organization Trial Identifier NCT Trial Identifier Title Trial Type Primary Purpose If Primary Purpose is 'Other', describe Phase Pilot Trial? [Site Principal Investigator] Person PO-ID [Site Principal Investigator] First Name [Site Principal Investigator] Middle Name [Site Principal Investigator] Last Name [Site Principal Investigator] Street Address [Site Principal Investigator] City [Site Principal Investigator] State/Province [Site Principal Investigator] Zip/Postal code [Site Principal Investigator] Country [Site Principal Investigator] Email Address [Site Principal Investigator] Phone [Site Principal Investigator] TTY Site [Principal Investigator] FAX [Site Principal Investigator] URL Summary 4 Funding Sponsor/Source Category [Summary 4 Funding Sponsor/Source] Organization PO-ID [Summary 4 Funding Sponsor/Source] Organization Name [Summary 4 Funding Sponsor/Source] Street Address [Summary 4 Funding Sponsor/Source] City [Summary 4 Funding Sponsor/Source] State/Province [Summary 4 Funding Sponsor/Source] Zip/Postal code [Summary 4 Funding Sponsor/Source ] Country [Summary 4 Funding Sponsor/Source ] Email Address [Summary 4 Funding Sponsor/Source ] Phone [Summary 4 Funding Sponsor/Source ] TTY [Summary 4 Funding Sponsor/Source ] FAX [Summary 4 Funding Sponsor/Source ] URL [Submitting Site specific] Program Code Site Recruitment Status Site Recruitment Status Date Date Opened for Accrual Date Closed for Accrual Site Target Accrual Disease Name Intervention Type Intervention Name Trial Owner First Name Trial Owner Last Name Trial Owner Email Address

1 O

Mayo Clinic Hospital 5777 East Mayo Boulevard Phoeniz AZ 85054 United States [email protected]



Research Based Yes 12345










cancer center

Phase III study of priming with granulocyte-macrophage colony stimulating factor (rhu-gm-csf)and of three induction regimens in adult patients (over 55) with acute non-lymphocytic leukemia Interventional Other Laboratory III

Harry
Long 5777 East Mayo Boulevard Phoeniz AZ 85054 United States [email protected] 123-345-7654


Industrial
Novartis Pharmaceuticals Corporation One Health Plaza East Hanover NJ 07936-1080 United States [email protected]




Active 03/01/2009 03/01/2009
50 acute non-lymphocytic leukemia Biological/Vaccine granulocyte-macrophage colony stimulating factor Mary Smith [email protected]

1





































































stage III non-lymphocytic leukemia










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sheet 5: Abbreviated Trial Data Spec

Trial elements Order Trial data element Required? Valid Values Comments Definition
1 Local Trial Identifier Yes
Trial identifier as assigned by the submitting organization
2 Submission Type Yes O, U O- Original is default. U-update Original submission is the first time submission of a trial to CTRP. Update means submitting an update to the already registered trial in CTRP.
3 NCI Trial Identifier Yes for submitting update only
Ignored in case of original submission
4 [Submitting Organization] Organization PO-ID

PO-ID or all organization mandatory attributes are required
5 [Submitting Organization] Name Yes if PO-ID is not provided


6 [Submitting Organization] Street Address Yes if PO-ID is not provided


7 [Submitting Organization] City Yes if PO-ID is not provided


8 [Submitting Organization] State/Province Yes for US/Canada/Australia and if PO-ID is not provided 2-letter state/province code required for US/Canada, 2-3 letter code required for Australia

9 [Submitting Organization] Zip/Postal code Yes if PO-ID is not provided


10 [Submitting Organization] Country Yes if PO-ID is not provided


11 [Submitting Organization] Email Address Yes if PO-ID is not provided


12 [Submitting Organization] Phone

Include Phone Extension if any in the same field
13 [Submitting Organization] TTY



14 [Submitting Organization] FAX



15 [Submitting Organization] URL



16 [Submitting Organization] Organization Type
Institution, ordering group, repository, research based, cooperative group, cancer center, consortium, drug company, network

17 Is Submitting Organization a NCI Designated Cancer Center? Yes yes, no no is default
18 [Lead Organization] CTEP Organization PO-ID

PO-ID or all organization mandatory attributes is required
19 [Lead Organization] Name Yes if PO-ID is not provided


20 [Lead Organization] Street Address Yes if PO-ID is not provided


21 [Lead Organization] City Yes if PO-ID is not provided


22 [Lead Organization] State/Province Yes for US/Canada/Australia and if PO-ID is not provided 2-letter state/province code required for US/Canada, 2-3 letter code required for Australia

23 [Lead Organization] Zip/Postal code Yes if PO-ID is not provided


24 [Lead Organization] Country Yes if PO-ID is not provided


25 [Lead Organization] Email Address Yes if PO-ID is not provided


26 [Lead Organization] Phone Yes if PO-ID is not provided
Include Phone Extension if any in the same field
27 [Lead Organization] TTY



28 [Lead Organization] FAX



29 [Lead Organization] URL



30 [Lead Organization] Organization Type
Institution, ordering group, repository, research based, cooperative group, cancer center, consortium, drug company, network

31 Lead Organization Trial Identifier Yes
AS IS in the protocol document & assigned by the lead organization
32 NCT Trial Identifier

This value or at least one disease and one intervention record are required in attached proprietary trial template
33 Title Yes Max 4000 characters Title from the protocol document
34 Trial Type Yes Interventional, Observational Currently only Interventional trials are accepted
35 Primary Purpose Yes, if NCT number is not provided Treatment, Prevention, Supportive Care, Screening, Diagnostic, Health Service Research, Basic Science, Other Mandatory if value in row 32 is NULL (if NCT number is NULL)
36 If Primary Purpose is 'Other', describe Yes, if Primary Purpose value is 'Other'
Provide free text value if Primary Purpose value is 'Other'. Not aplicable if Primary Purpose is not 'Other'
37 Phase Yes, if NCT number is not provided 0, I, I/II, II, II/III, III, IV, N/A Mandatory if value in row 32 is NULL (if NCT number is NULL)
38 Pilot Trial?
Yes, No Only applicable if Phase is 'N/A; Default is No
39 [Site Principal Investigator] Person PO-ID

PO-ID or all mandatory person attributes are required
40 [Site Principal Investigator] First Name Yes if PO-ID is not provided


41 [Site Principal Investigator] Middle Name



42 [Site Principal Investigator] Last Name Yes if PO-ID is not provided


43 [Site Principal Investigator] Street Address Yes if PO-ID is not provided


44 [Site Principal Investigator] City Yes if PO-ID is not provided


45 [Site Principal Investigator] State/Province Yes for US/Canada/Australia and if PO-ID is not provided 2-letter state/province code required for US/Canada, 2-3 letter code required for Australia

46 [Site Principal Investigator] Zip/Postal code Yes if PO-ID is not provided


47 [Site Principal Investigator] Country Yes if PO-ID is not provided


48 [Site Principal Investigator] Email Address Yes if PO-ID is not provided


49 [Site Principal Investigator] Phone Yes if PO-ID is not provided
Include Phone Extension if any in the same field
50 [Site Principal Investigator] TTY



51 Site [Principal Investigator] FAX



52 [Site Principal Investigator] URL



53 Summary 4 Funding Sponsor/Source Category Yes Industrial

54 [Summary 4 Funding Sponsor/Source] Organization PO-ID PO-ID or the rest of mandatory attribute for the organization is mandatory


55 [Summary 4 Funding Sponsor/Source] Organization Name Yes if PO-ID is not provided


56 [Summary 4 Funding Sponsor/Source] Street Address Yes if PO-ID is not provided


57 [Summary 4 Funding Sponsor/Source] City Yes if PO-ID is not provided


58 [Summary 4 Funding Sponsor/Source] State/Province Yes if PO-ID is not provided and for the following courtiers: USA, Canada and Australia 2-letter state/province code required for US/Canada, 2-3 letter code required for Australia

59 [Summary 4 Funding Sponsor/Source] Zip/Postal code Yes if PO-ID is not provided


60 [Summary 4 Funding Sponsor/Source ] Country Yes if PO-ID is not provided


61 [Summary 4 Funding Sponsor/Source ] Email Address Yes if PO-ID is not provided


62 [Summary 4 Funding Sponsor/Source ] Phone



63 [Summary 4 Funding Sponsor/Source ] TTY



64 [Summary 4 Funding Sponsor/Source ] FAX



65 [Summary 4 Funding Sponsor/Source ] URL



66 [Submitting Site specific] Program Code Yes for NCI designated cancer center Submitting Site specific Submitting Site specific, 'Not specified' is default. Mandatory if value in row 17 is 'yes'.
67 Site Recruitment Status Yes Not yet recruiting; Recruiting; Enrolling by invitation; Active, not recruiting; Completed; Suspended; Terminated; Withdrawn

68 Site Recruitment Status Date Yes
Date when the recruitment status has come in effect
69 Date Opened for Accrual Yes if study is or was opened for accrual


70 Date Closed for Accrual Yes if study is or was closed for accrual


71 Site Target Accrual Yes for NCI designated Cancer Center
Mandatory if value in row 17 is 'yes'. '0' can be used if value is unknown
72 Disease Name Yes if NCT number is not provided
If more that one disease is provided, use the additional line for a new disease (see Trial Data Sample)
73 Intervention Type Yes if NCT number is not provided Drug, Device, Biological/Vaccine, Procedure/Surgery, Radiation, Behavioral, Genetic, Dietary Supplement, Other If more that one intervention is provided, use the additional line for an additional intervention (see Trial Data Sample)
74 Intervention Name Yes if NCT number is not provided
If more that one intervention is provided, use the additional line for an additional intervention (see Trial Data Sample)
75 Trial Owner First Name Yes
This information is required for trial ownership transfer. Note: user must be registered in CTRP
76 Trial Owner Last Name Yes
This information is required for trial ownership transfer. Note: user must be registered in CTRP
77 Trial Owner Email Address Yes
This information is required for trial ownership transfer. Note: user must be registered in CTRP

Sheet 6: 2-letter state_province

Country Country 3-letter code State/Province 2-3 letter state/province code Old values
UNITED STATES USA




Alabama AL


Alaska AK


Arizona AZ


Arkansas AR


California CA


Colorado CO


Connecticut CT


Delaware DE


Florida FL


Georgia GA


Hawaii HI


Idaho ID


Illinois IL


Indiana IN


Iowa IA


Kansas KS


Kentucky KY


Louisiana LA


Maine ME


Maryland MD


Massachusetts MA


Michigan MI


Minnesota MN


Mississippi MS


Missouri MO


Montana MT


Nebraska NE


Nevada NV


New Hampshire NH


New Jersey NJ


New Mexico NM


New York NY


North Carolina NC


North Dakota ND


Ohio OH


Oklahoma OK


Oregon OR


Pennsylvania PA


Rhode Island RI


South Carolina SC


South Dakota SD


Tennessee TN


Texas TX


Utah UT


Vermont VT


Virginia VA


Washington WA


West Virginia WV


Wisconsin WI


Wyoming WY
CANADA CAN




Alberta AB


British Columbia BC


Manitoba MB


New Brunswick NB


Newfoundland and Labrador NL


Northwest Territories NT


Nova Scotia NS


Nunavut NU


Ontario ON


Prince Edward Island PE


Quebec QC


Saskatchewan SK


Yukon YT
AUSTRIA AUT




Australian Capital Territory ACT


New South Wales NSW


Northern Territory NT


Queensland QLD


South Australia SA


Tasmania TAS


Victoria VIC


Western Australia WA
File Typeapplication/vnd.ms-excel
File TitleCTRP Trial Registration Batch Upload Specification
SubjectCTRP Trial Registration Batch Upload Specification
AuthorBala Nair, ScenPro, Inc
Last Modified ByDavid Loose
File Modified2013-04-03
File Created2007-12-27

© 2024 OMB.report | Privacy Policy